1887
Review Open Access
Like 0

Abstract

Introduction: Although human papillomavirus (HPV) routine vaccination programmes have been implemented around the world and recommendations have been expanded to include other high-risk individuals, current recommendations often differ between countries in Europe, as well as worldwide.

Aim: To find and summarise the best available evidence of HPV vaccination in high-risk patients aiding clinicians and public health workers in the day-to-day vaccine decisions relating to HPV in Spain.

Methods: We conducted a systematic review of the immunogenicity, safety and efficacy/effectiveness of HPV vaccination in high-risk populations between January 2006 and June 2016. HPV vaccination recommendations were established with levels of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system.

Results: A strong recommendation about HPV vaccination was made in the following groups: HIV infected patients aged 9–26 years; men who have sex with men aged 9–26 years; women with precancerous cervical lesions; patients with congenital bone marrow failure syndrome; women who have received a solid organ transplant or hematopoietic stem cell transplantation aged 9–26 years; and patients diagnosed with recurrent respiratory papillomatosis.

Conclusions: Data concerning non-routine HPV vaccination in populations with a high risk of HPV infection and associated lesions were scarce. We have developed a document to evaluate and establish evidence-based guidelines on HPV vaccination in high-risk populations in Spain, based on best available scientific evidence.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2019.24.7.1700857
2019-02-14
2019-09-23
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2019.24.7.1700857
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/24/7/eurosurv-24-7-2.html?itemId=/content/10.2807/1560-7917.ES.2019.24.7.1700857&mimeType=html&fmt=ahah

References

  1. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244-65.  https://doi.org/10.1136/jcp.55.4.244  PMID: 11919208 
  2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-9.  https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F  PMID: 10451482 
  3. Alemany L, Saunier M, Tinoco L, Quirós B, Alvarado-Cabrero I, Alejo M, et al. HPV VVAP study group. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur J Cancer. 2014;50(16):2846-54.  https://doi.org/10.1016/j.ejca.2014.07.018  PMID: 25155250 
  4. de Sanjosé S, Alemany L, Ordi J, Tous S, Alejo M, Bigby SM, et al. HPV VVAP study group. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer. 2013;49(16):3450-61.  https://doi.org/10.1016/j.ejca.2013.06.033  PMID: 23886586 
  5. Alemany L, Cubilla A, Halec G, Kasamatsu E, Quirós B, Masferrer E, et al. HPV VVAP study group. Role of Human Papillomavirus in Penile Carcinomas Worldwide. Eur Urol. 2016;69(5):953-61.  https://doi.org/10.1016/j.eururo.2015.12.007  PMID: 26762611 
  6. Alemany L, Saunier M, Alvarado-Cabrero I, Quirós B, Salmeron J, Shin HR, et al. HPV VVAP Study Group. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2015;136(1):98-107.  https://doi.org/10.1002/ijc.28963  PMID: 24817381 
  7. Castellsagué X, Alemany L, Quer M, Halec G, Quirós B, Tous S, et al. ICO International HPV in Head and Neck Cancer Study Group. HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. J Natl Cancer Inst. 2016;108(6):djv403.  https://doi.org/10.1093/jnci/djv403  PMID: 26823521 
  8. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805-14.  https://doi.org/10.1086/597071  PMID: 19199546 
  9. Gillison ML, Alemany L, Snijders PJ, Chaturvedi A, Steinberg BM, Schwartz S, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine. 2012;30(Suppl 5):F34-54.  https://doi.org/10.1016/j.vaccine.2012.05.070  PMID: 23199965 
  10. Castellsagué X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol. 2008;110(3) Suppl 2;S4-7.  https://doi.org/10.1016/j.ygyno.2008.07.045  PMID: 18760711 
  11. Giuliano AR, Anic G, Nyitray AG. Epidemiology and pathology of HPV disease in males. Gynecol Oncol. 2010;117(2) Suppl;S15-9.  https://doi.org/10.1016/j.ygyno.2010.01.026  PMID: 20138345 
  12. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664-70.  https://doi.org/10.1002/ijc.30716  PMID: 28369882 
  13. Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of HPV-related disease. Best Pract Res Clin Obstet Gynaecol. 2018;47:14-26.  https://doi.org/10.1016/j.bpobgyn.2017.08.006  PMID: 29037457 
  14. World Health Organization (WHO). Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec. 2017;92(19):241-68. PMID: 28530369 
  15. GlaxoSmithKline. Cervarix suspension for injection: summary of product characteristics: GlaxoSmithKline; 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000721/WC500024632.pdf
  16. Merck Sharp & Dohme BV. Gardasil suspension for injection: summary of product characteristics. Stockholm: Merck Sharp & Dohme BV;2011. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000703/WC500021142.pdf
  17. Merck Sharp & Dohme BV. Gardasil 9 suspension for injection: summary of product characteristics. Merck Sharp & Dohme BV; 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003852/WC500189111.pdf
  18. European Centre for Disease Prevention and Control (ECDC). Vaccine schedules in all countries of the European Union. Stockholm: ECDC. Available from: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx [Accessed 3 Jul 2018].
  19. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1-30. PMID: 25167164 
  20. Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CBAdvisory Committee on Immunization Practices. Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017. Ann Intern Med. 2017;166(3):209-19.  https://doi.org/10.7326/M16-2936  PMID: 28166560 
  21. Australian Technical Advisory Group on Immunisation (ATAGI). The Australian immunisation handbook 10th ed (2015 update). Canberra: Australian Government Department of Health; 2015.
  22. National Advisory Committee on Immunization (NACI). Update on the recommended Human Papillomavirus (HPV) vaccine immunization schedule. Ottawa: NACI; 2015. Available from: http://www.phac-aspc.gc.ca/naci-ccni/acs-dcc/2015/hpv-vph_0215-eng.php
  23. Public Health England (PHE). Human papillomavirus (HPV) vaccination for Men who have sex with Men (MSM) 2016/17 pilot evaluation. London: PHE; 2016. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/678987/HPV_msm_year1_evaluation_report.pd
  24. Asociación Española de Patología Cervicaly Colposcopia (AEPCC). Vacunación selectiva frente al virus del papiloma humano en poblaciones de riesgo elevado. [Selective vaccination against human papillomavirus in high-risk populations].AEPCC; 2016. Spanish. Available from: http://www.aepcc.org/wp-content/uploads/2016/12/AEPCC_revista07_VACUNACION-SELECTIVA.pdf
  25. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-74.  https://doi.org/10.2307/2529310  PMID: 843571 
  26. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719-25.  PMID: 23312392 
  27. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44-100.  https://doi.org/10.1093/cid/cit684  PMID: 24311479 
  28. Darwich L, Cañadas MP, Videla S, Coll J, Molina-López RA, Sirera G, et al. Can Ruti HIV-HPV Team. Prevalence, clearance, and incidence of human papillomavirus type-specific infection at the anal and penile site of HIV-infected men. Sex Transm Dis. 2013;40(8):611-8.  https://doi.org/10.1097/01.OLQ.0000430798.61475.08  PMID: 23859907 
  29. de Pokomandy A, Rouleau D, Ghattas G, Vézina S, Coté P, Macleod J, et al. HIPVIRG Study Group. Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J Infect Dis. 2009;199(7):965-73.  https://doi.org/10.1086/597207  PMID: 19239366 
  30. Geskus RB, González C, Torres M, Del Romero J, Viciana P, Masiá M, et al. CoRIS-HPV Study Group. Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men: estimates and risk factors. AIDS. 2016;30(1):37-44. PMID: 26355673 
  31. Silverberg MJ, Lau B, Justice AC, Engels E, Gill MJ, Goedert JJ, et al. North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012;54(7):1026-34.  https://doi.org/10.1093/cid/cir1012  PMID: 22291097 
  32. Conley LJ, Ellerbrock TV, Bush TJ, Chiasson MA, Sawo D, Wright TC. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet. 2002;359(9301):108-13.  https://doi.org/10.1016/S0140-6736(02)07368-3  PMID: 11809252 
  33. Massad LS, Silverberg MJ, Springer G, Minkoff H, Hessol N, Palefsky JM, et al. Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virus. Am J Obstet Gynecol. 2004;190(5):1241-8.  https://doi.org/10.1016/j.ajog.2003.12.037  PMID: 15167825 
  34. Darwich L, Cañadas MP, Videla S, Coll J, Piñol M, Cobarsi P, et al. HIV-HPV Can Ruti Team. Condylomata, cytological abnormalities and human papillomavirus infection in the anal canal in HIV-infected men. HIV Med. 2012;13(9):549-57.  https://doi.org/10.1111/j.1468-1293.2012.01013.x  PMID: 22435501 
  35. Levin MJ, Moscicki AB, Song LY, Fenton T, Meyer WA 3rd, Read JS, et al. IMPAACT P1047 Protocol Team. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr. 2010;55(2):197-204.  https://doi.org/10.1097/QAI.0b013e3181de8d26  PMID: 20574412 
  36. Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis. 2013;57(5):735-44.  https://doi.org/10.1093/cid/cit319  PMID: 23667266 
  37. Giacomet V, Penagini F, Trabattoni D, Viganò A, Rainone V, Bernazzani G, et al. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine. 2014;32(43):5657-61.  https://doi.org/10.1016/j.vaccine.2014.08.011  PMID: 25149430 
  38. Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine. 2013;31(48):5745-53.  https://doi.org/10.1016/j.vaccine.2013.09.032  PMID: 24091311 
  39. Kojic EM, Kang M, Cespedes MS, Umbleja T, Godfrey C, Allen RT, et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis. 2014;59(1):127-35.  https://doi.org/10.1093/cid/ciu238  PMID: 24723284 
  40. Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010;202(8):1246-53.  https://doi.org/10.1086/656320  PMID: 20812850 
  41. Toft L, Storgaard M, Müller M, Sehr P, Bonde J, Tolstrup M, et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis. 2014;209(8):1165-73.  https://doi.org/10.1093/infdis/jit657  PMID: 24273179 
  42. Money DM, Moses E, Blitz S, Vandriel SM, Lipsky N, Walmsley SL, et al. HPV in HIV Study Group. HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine. Vaccine. 2016;34(40):4799-806.  https://doi.org/10.1016/j.vaccine.2016.08.016  PMID: 27544584 
  43. Fontes A, Andreoli MA, Villa LL, Assone T, Gaester K, Fonseca LAM, et al. High specific immune response to a bivalent anti-HPV vaccine in HIV-1-infected men in São Paulo, Brazil. Papillomavirus Res. 2016;2:17-20.  https://doi.org/10.1016/j.pvr.2016.01.001  PMID: 29074177 
  44. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576-85.  https://doi.org/10.1056/NEJMoa1010971  PMID: 22029979 
  45. Washington University School of Medicine. The effect of HPV vaccination on recurrence rates in HIV patients with condylomata. St Louis: Washington University School of Medicine; 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT00941889
  46. University of the Witwatersrand. Randomized, double blind trial of the quadrivalent HPV vaccine to improve responses to LEEP treatment of cervical HSIL. Johannesburg: University of the Witwatersrand; 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT01928225
  47. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). HPV (human papilloma virus) vaccination after treatment of anal intraepithelial neoplasia (AIN) (VACCAIN-P). Amsterdam: AMC-UVA; 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT02087384
  48. European AIDS Clinical Society (EACS). Clinical management and treatment of HIV infected adults in Europe, version 8.0. Brussels: EACS; 2015. Available from: http://www.eacsociety.org/files/2015_eacsguidelines_8_0-english_rev-20160124.pdf
  49. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. [Accessed 3 Jul 2018]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf.
  50. D’Souza G, Wiley DJ, Li X, Chmiel JS, Margolick JB, Cranston RD, et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2008;48(4):491-9.  https://doi.org/10.1097/QAI.0b013e31817aebfe  PMID: 18614927 
  51. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101(2):270-80.  https://doi.org/10.1002/cncr.20365  PMID: 15241823 
  52. Goldstone SE, Hundert JS, Huyett JW. Infrared coagulator ablation of high-grade anal squamous intraepithelial lesions in HIV-negative males who have sex with males. Dis Colon Rectum. 2007;50(5):565-75.  https://doi.org/10.1007/s10350-006-0874-x  PMID: 17380365 
  53. Centers for Disease Control and Prevention (CDC). Sexually transmitted disease surveillance 2014. Atlanta: CDC;2015. Available from: http://www.cdc.gov/std/stats14/surv-2014-print.pdf
  54. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364(5):401-11.  https://doi.org/10.1056/NEJMoa0909537  PMID: 21288094 
  55. Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Vardas E, et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol. 2012;19(2):261-7.  https://doi.org/10.1128/CVI.05208-11  PMID: 22155768 
  56. Swedish KA, Goldstone SE. Prevention of anal condyloma with quadrivalent human papillomavirus vaccination of older men who have sex with men. PLoS One. 2014;9(4):e93393.  https://doi.org/10.1371/journal.pone.0093393  PMID: 24714693 
  57. Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis. 2012;54(7):891-8.  https://doi.org/10.1093/cid/cir1036  PMID: 22291111 
  58. Castellsagué X, Giuliano AR, Goldstone S, Guevara A, Mogensen O, Palefsky JM, et al. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015;33(48):6892-901.  https://doi.org/10.1016/j.vaccine.2015.06.088  PMID: 26144901 
  59. Seksik P, Cosnes J, Sokol H, Nion-Larmurier I, Gendre JP, Beaugerie L. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. Aliment Pharmacol Ther. 2009;29(10):1106-13.  https://doi.org/10.1111/j.1365-2036.2009.03973.x  PMID: 19222411 
  60. Somasekar A, Alcolado R. Genital condylomata in a patient receiving infliximab for Crohn’s disease. Postgrad Med J. 2004;80(944):358-9.  https://doi.org/10.1136/pgmj.2003.009332  PMID: 15192172 
  61. Antoniou C, Kosmadaki MG, Stratigos AJ, Katsambas AD. Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy. Dermatology. 2008;216(4):364-5.  https://doi.org/10.1159/000117709  PMID: 18285688 
  62. Handisurya A, Lázár S, Papay P, Primas C, Haitel A, Horvat R, et al. Anogenital Human Papillomavirus Prevalence is Unaffected by Therapeutic Tumour Necrosis Factor-alpha Inhibition. Acta Derm Venereol. 2016;96(4):494-8.  https://doi.org/10.2340/00015555-2298  PMID: 26581127 
  63. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103(3):631-6.  https://doi.org/10.1111/j.1572-0241.2007.01582.x  PMID: 17941962 
  64. Bhatia J, Bratcher J, Korelitz B, Vakher K, Mannor S, Shevchuk M, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol. 2006;12(38):6167-71.  https://doi.org/10.3748/wjg.v12.i38.6167  PMID: 17036389 
  65. Jess T, Horváth-Puhó E, Fallingborg J, Rasmussen HH, Jacobsen BA. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol. 2013;108(12):1869-76.  https://doi.org/10.1038/ajg.2013.249  PMID: 23978954 
  66. Rungoe C, Simonsen J, Riis L, Frisch M, Langholz E, Jess T. Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study. Clin Gastroenterol Hepatol. 2015;13(4):693-700.e1.
  67. Singh H, Demers AA, Nugent Z, Mahmud SM, Kliewer EV, Bernstein CN. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology. 2009;136(2):451-8.  https://doi.org/10.1053/j.gastro.2008.10.021  PMID: 18996382 
  68. Lees CW, Critchley J, Chee N, Beez T, Gailer RE, Williams AR, et al. Lack of association between cervical dysplasia and IBD: a large case-control study. Inflamm Bowel Dis. 2009;15(11):1621-9.  https://doi.org/10.1002/ibd.20959  PMID: 19618462 
  69. Jacobson DL, Bousvaros A, Ashworth L, Carey R, Shrier LA, Burchett SK, et al. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(7):1441-9.  https://doi.org/10.1097/MIB.0b013e318281341b  PMID: 23567780 
  70. Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, et al. ECCO. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohn’s Colitis. 2015;9(11):945-65.  https://doi.org/10.1093/ecco-jcc/jjv141  PMID: 26294789 
  71. Campins M, Cossio Y, Martínez X, Borruel N. Vaccination of patients with inflammatory bowel disease. Practical recommendations. Rev Esp Enferm Dig. 2013;105(2):93-102.  https://doi.org/10.4321/S1130-01082013000200006  PMID: 23659508 
  72. Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn’s Colitis. 2014;8(6):443-68.  https://doi.org/10.1016/j.crohns.2013.12.013  PMID: 24613021 
  73. Magro F, Peyrin-Biroulet L, Sokol H, Aldeger X, Costa A, Higgins PD, et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohn’s Colitis. 2014;8(1):31-44.  https://doi.org/10.1016/j.crohns.2013.04.006  PMID: 23721759 
  74. Castellsagué X, Iftner T, Roura E, Vidart JA, Kjaer SK, Bosch FX, et al. Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: the CLEOPATRE study. J Med Virol. 2012;84(6):947-56.  https://doi.org/10.1002/jmv.23282  PMID: 22499018 
  75. Torné Bladé A, Bayas Rodríguez JM, Castellsagué Piqué X, Castro Sánchez M, García García E, Martínez Escoriza JC, et al. Vacunación frente al cáncer de cérvix en mujeres fuera de los programas de vacunación sistemática, con o sin infección por el virus del papiloma humano o lesión cervical. Encuesta de opinión y recomendaciones. [Vaccination against cervical cancer in women outside of routine vaccination programs, with or without human papillomavirus infection or cervical lesion. Survey of opinion and recommendations]. Prog Obs Ginecol.2012;55(Suppl 1):10-31.  https://doi.org/10.1016/S0304-5013(12)73065-0 
  76. Kocken M, Helmerhorst TJ, Berkhof J, Louwers JA, Nobbenhuis MA, Bais AG, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol. 2011;12(5):441-50.  https://doi.org/10.1016/S1470-2045(11)70078-X  PMID: 21530398 
  77. Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011;105(1):28-37.  https://doi.org/10.1038/bjc.2011.185  PMID: 21629249 
  78. Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmerón J, et al. VIVIANE Study Group. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014;384(9961):2213-27.  https://doi.org/10.1016/S0140-6736(14)60920-X  PMID: 25189358 
  79. Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ. 2012;344:e1401. PMID: 22454089 
  80. Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol Oncol. 2013;130(2):264-8.  https://doi.org/10.1016/j.ygyno.2013.04.050  PMID: 23623831 
  81. Garland SM, Paavonen J, Jaisamrarn U, Naud P, Salmerón J, Chow SN, et al. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial. Int J Cancer. 2016;139(12):2812-26.  https://doi.org/10.1002/ijc.30391  PMID: 27541373 
  82. Dokal I, Vulliamy T. Inherited aplastic anaemias/bone marrow failure syndromes. Blood Rev. 2008;22(3):141-53.  https://doi.org/10.1016/j.blre.2007.11.003  PMID: 18164793 
  83. Leiding JW, Holland SM. Warts and all: human papillomavirus in primary immunodeficiencies. J Allergy Clin Immunol. 2012;130(5):1030-48.  https://doi.org/10.1016/j.jaci.2012.07.049  PMID: 23036745 
  84. Savani BN, Stratton P, Shenoy A, Kozanas E, Goodman S, Barrett AJ. Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation--implications for screening and HPV vaccination. Biol Blood Marrow Transplant. 2008;14(9):1072-5.  https://doi.org/10.1016/j.bbmt.2008.07.005  PMID: 18721771 
  85. Ojha RP, Tota JE, Offutt-Powell TN, Klosky JL, Minniear TD, Jackson BE, et al. Human papillomavirus-associated subsequent malignancies among long-term survivors of pediatric and young adult cancers. PLoS One. 2013;8(8):e70349.  https://doi.org/10.1371/journal.pone.0070349  PMID: 23940566 
  86. Katzenellenbogen RA, Carter JJ, Stern JE, Butsch Kovacic MS, Mehta PA, Sauter SL, et al. Skin and mucosal human papillomavirus seroprevalence in persons with Fanconi Anemia. Clin Vaccine Immunol. 2015;22(4):413-20.  https://doi.org/10.1128/CVI.00665-14  PMID: 25651924 
  87. Kroger AT, Atkinson WL, Marcuse EK, Pickering LKAdvisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-15):1-48. PMID: 17136024 
  88. Handisurya A, Schellenbacher C, Reininger B, Koszik F, Vyhnanek P, Heitger A, et al. A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome. Vaccine. 2010;28(30):4837-41.  https://doi.org/10.1016/j.vaccine.2010.04.057  PMID: 20472031 
  89. Children’s Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers - Version 4.0, October2013. [Accessed 3 Jul 2018]. Available from: http://www.survivorshipguidelines.org/pdf/LTFUGuidelines_40.pdf
  90. Klosky JL, Foster RH, Hodges J, Peasant C, Gamble H, McDermott MJ, et al. Human papillomavirus vaccination and the primary prevention of cancer: implications for survivors of childhood cancer. Stud Health Technol Inform. 2012;172:33-42. PMID: 22910499 
  91. Rose B, Wilkins D, Li W, Tran N, Thompson C, Cossart Y, et al. Human papillomavirus in the oral cavity of patients with and without renal transplantation. Transplantation. 2006;82(4):570-3.  https://doi.org/10.1097/01.tp.0000231706.79165.e5  PMID: 16926603 
  92. Reuschenbach M, Tran T, Faulstich F, Hartschuh W, Vinokurova S, Kloor M, et al. High-risk human papillomavirus in non-melanoma skin lesions from renal allograft recipients and immunocompetent patients. Br J Cancer. 2011;104(8):1334-41.  https://doi.org/10.1038/bjc.2011.95  PMID: 21427726 
  93. Meeuwis KA, Melchers WJ, Bouten H, van de Kerkhof PC, Hinten F, Quint WG, et al. Anogenital malignancies in women after renal transplantation over 40 years in a single center. Transplantation. 2012;93(9):914-22.  https://doi.org/10.1097/TP.0b013e318249b13d  PMID: 22377788 
  94. Park ST, Song MJ, Park JS, Hur SY, Lee CW. Incidence and clinicopathologic behavior of uterine cervical carcinoma in renal transplant recipients. World J Surg Oncol. 2011;9(1):72.  https://doi.org/10.1186/1477-7819-9-72  PMID: 21752252 
  95. Patel HS, Silver AR, Levine T, Williams G, Northover JM. Human papillomavirus infection and anal dysplasia in renal transplant recipients. Br J Surg. 2010;97(11):1716-21.  https://doi.org/10.1002/bjs.7218  PMID: 20730855 
  96. Meeuwis KA, Hilbrands LB, IntHout J, Slangen BF, Hendriks IM, Hinten F, et al. Cervicovaginal HPV infection in female renal transplant recipients: an observational, self-sampling based, cohort study. Am J Transplant. 2015;15(3):723-33.  PMID: 25675976 
  97. Adami J, Gäbel H, Lindelöf B, Ekström K, Rydh B, Glimelius B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89(7):1221-7.  https://doi.org/10.1038/sj.bjc.6601219  PMID: 14520450 
  98. Meeuwis KA, van Rossum MM, van de Kerkhof PC, Hoitsma AJ, Massuger LF, de Hullu JA. Skin cancer and (pre)malignancies of the female genital tract in renal transplant recipients. Transpl Int. 2010;23(2):191-9.  https://doi.org/10.1111/j.1432-2277.2009.00975.x  PMID: 19793075 
  99. Kolb HJ, Socié G, Duell T, Van Lint MT, Tichelli A, Apperley JF, et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Ann Intern Med. 1999;131(10):738-44.  https://doi.org/10.7326/0003-4819-131-10-199911160-00004  PMID: 10577296 
  100. Bhatia S, Louie AD, Bhatia R, O’Donnell MR, Fung H, Kashyap A, et al. Solid cancers after bone marrow transplantation. J Clin Oncol. 2001;19(2):464-71.  https://doi.org/10.1200/JCO.2001.19.2.464  PMID: 11208840 
  101. Rizzo JD, Curtis RE, Socié G, Sobocinski KA, Gilbert E, Landgren O, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009;113(5):1175-83.  https://doi.org/10.1182/blood-2008-05-158782  PMID: 18971419 
  102. Savani BN, Goodman S, Barrett AJ. Can routine posttransplant HPV vaccination prevent commonly occurring epithelial cancers after allogeneic stem cell transplantation? Clin Cancer Res. 2009;15(7):2219-21.  https://doi.org/10.1158/1078-0432.CCR-08-3099  PMID: 19293253 
  103. Wang Y, Brinch L, Jebsen P, Tanbo T, Kirschner R. A clinical study of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(5):747-53.  https://doi.org/10.1016/j.bbmt.2011.09.012  PMID: 21963879 
  104. Kumar D, Unger ER, Panicker G, Medvedev P, Wilson L, Humar A. Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. Am J Transplant. 2013;13(9):2411-7.  https://doi.org/10.1111/ajt.12329  PMID: 23837399 
  105. Gomez-Lobo V, Whyte T, Kaufman S, Torres C, Moudgil A. Immunogenicity of a prophylactic quadrivalent human papillomavirus L1 virus-like particle vaccine in male and female adolescent transplant recipients. Pediatr Transplant. 2014;18(3):310-5.  https://doi.org/10.1111/petr.12226  PMID: 24484551 
  106. Nelson DR, Neu AM, Abraham A, Amaral S, Batisky D, Fadrowski JJ. Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD. Clin J Am Soc Nephrol. 2016;11(5):776-84.  https://doi.org/10.2215/CJN.09690915  PMID: 27055465 
  107. Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine. 2006;24 Suppl 3:S3/140-6.
  108. Reusser NM, Downing C, Guidry J, Tyring SK. HPV Carcinomas in Immunocompromised Patients. J Clin Med. 2015;4(2):260-81.  https://doi.org/10.3390/jcm4020260  PMID: 26239127 
  109. Grein IH, Groot N, Lacerda MI, Wulffraat N, Pileggi G. HPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should know. Pediatr Rheumatol Online J. 2016;14(1):12.  https://doi.org/10.1186/s12969-016-0072-x  PMID: 26956735 
  110. Santana IU, Gomes AN, Lyrio LD, Rios Grassi MF, Santiago MB. Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. Clin Rheumatol. 2011;30(5):665-72.  https://doi.org/10.1007/s10067-010-1606-0  PMID: 21072553 
  111. Zard E, Arnaud L, Mathian A, Chakhtoura Z, Hie M, Touraine P, et al. Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature. Autoimmun Rev. 2014;13(7):730-5.  https://doi.org/10.1016/j.autrev.2014.03.001  PMID: 24657969 
  112. Lyrio LD, Grassi MF, Santana IU, Olavarria VG, Gomes AN, CostaPinto L, et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int. 2013;33(2):335-40.  https://doi.org/10.1007/s00296-012-2426-0  PMID: 22451033 
  113. Adams DR, Zaenglein AL, Hershey MS. Etanercept and warts. J Drugs Dermatol. 2004;3(6):601. PMID: 15624740 
  114. Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol. 2010;6(3):165-74.  https://doi.org/10.1038/nrrheum.2009.279  PMID: 20142812 
  115. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013;72(5):659-64.  https://doi.org/10.1136/annrheumdis-2012-201393  PMID: 22589375 
  116. Heijstek MW, Scherpenisse M, Groot N, Wulffraat NM, Van Der Klis FR. Immunogenicity of the bivalent human papillomavirus vaccine in adolescents with juvenile systemic lupus erythematosus or juvenile dermatomyositis. J Rheumatol. 2013;40(9):1626-7.  https://doi.org/10.3899/jrheum.130246  PMID: 23997002 
  117. Soybilgic A, Onel KB, Utset T, Alexander K, Wagner-Weiner L. Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years. Pediatr Rheumatol Online J. 2013;11(1):29.  https://doi.org/10.1186/1546-0096-11-29  PMID: 23924237 
  118. Heijstek MW, Scherpenisse M, Groot N, Tacke C, Schepp RM, Buisman AM, et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study. Ann Rheum Dis. 2014;73(8):1500-7.  https://doi.org/10.1136/annrheumdis-2013-203429  PMID: 23723319 
  119. Esposito S, Corona F, Barzon L, Cuoco F, Squarzon L, Marcati G, et al. Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis. Expert Rev Vaccines. 2014;13(11):1387-93.  https://doi.org/10.1586/14760584.2014.943195  PMID: 25066387 
  120. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70(3):414-22.  https://doi.org/10.1136/ard.2010.137216  PMID: 21131643 
  121. Carifi M, Napolitano D, Morandi M, Dall’Olio D. Recurrent respiratory papillomatosis: current and future perspectives. Ther Clin Risk Manag. 2015;11:731-8.  https://doi.org/10.2147/TCRM.S81825  PMID: 25999724 
  122. Chirilă M, Bolboacă SD. Clinical efficiency of quadrivalent HPV (types 6/11/16/18) vaccine in patients with recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol. 2014;271(5):1135-42.  https://doi.org/10.1007/s00405-013-2755-y  PMID: 24121781 
  123. Lindeberg H, Elbrønd O. Laryngeal papillomas: the epidemiology in a Danish subpopulation 1965-1984. Clin Otolaryngol Allied Sci. 1990;15(2):125-31.  https://doi.org/10.1111/j.1365-2273.1990.tb00444.x  PMID: 2350888 
  124. Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg. 1995;121(12):1386-91.  https://doi.org/10.1001/archotol.1995.01890120044008  PMID: 7488368 
  125. Förster G, Boltze C, Seidel J, Pawlita M, Müller A. [Juvenile laryngeal papillomatosis--immunisation with the polyvalent vaccine gardasil]. Laryngorhinootologie. 2008;87(11):796-9.  PMID: 18759217 
  126. Young DL, Moore MM, Halstead LA. The use of the quadrivalent human papillomavirus vaccine (gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma. J Voice. 2015;29(2):223-9.  https://doi.org/10.1016/j.jvoice.2014.08.003  PMID: 25619468 
  127. Mudry P, Vavrina M, Mazanek P, Machalova M, Litzman J, Sterba J. Recurrent laryngeal papillomatosis: successful treatment with human papillomavirus vaccination. Arch Dis Child. 2011;96(5):476-7.  https://doi.org/10.1136/adc.2010.198184  PMID: 21220258 
  128. Mészner Z, Jankovics I, Nagy A, Gerlinger I, Katona G. Recurrent laryngeal papillomatosis with oesophageal involvement in a 2 year old boy: successful treatment with the quadrivalent human papillomatosis vaccine. Int J Pediatr Otorhinolaryngol. 2015;79(2):262-6.  https://doi.org/10.1016/j.ijporl.2014.11.022  PMID: 25496821 
  129. Yi L, Vaudaux B, Sandu K, Nisa L. Prolonged remission of juvenile-onset respiratory papillomatosis: a post-expositional role of the tetravalent anti-HPV vaccine? Int J Pediatr Otorhinolaryngol. 2014;78(2):388-90.  https://doi.org/10.1016/j.ijporl.2013.12.013  PMID: 24388316 
  130. Hočevar-Boltežar I, Matičič M, Sereg-Bahar M, Gale N, Poljak M, Kocjan B, et al. Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol. 2014;271(12):3255-62.  https://doi.org/10.1007/s00405-014-3143-y  PMID: 24964770 
  131. Hermann JS, Weckx LY, Monteiro Nürmberger J, Santos Junior GF, Campos Pignatari AC, Nagata Pignatari SS. Effectiveness of the human papillomavirus (types 6, 11, 16, and 18) vaccine in the treatment of children with recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol. 2016;83:94-8.  https://doi.org/10.1016/j.ijporl.2016.01.032  PMID: 26968061 
  132. Pawlita M, Gissmann L. Rekurrierende respiratorische Papillomatose [Recurrent respiratory papillomatosis]. Dtsch Med Wochenschr. 2009;134:S100-S102.  PMID: 19353471 
/content/10.2807/1560-7917.ES.2019.24.7.1700857
Loading

Data & Media loading...

Supplementary data

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error